Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Outcomes of 1st Remission Induction Chemotherapy in Acute Myeloid Leukemia Cytogenetic Risk Groups

  • Zehra, Samreen (National Institute of Blood Disease and Bone Marrow Transplantation) ;
  • Najam, Rahela (Department of Pharmacology, Faculty of Pharmacy, University of Karachi) ;
  • Farzana, Tasneem (National Institute of Blood Disease and Bone Marrow Transplantation) ;
  • Shamsi, Tahir Sultan (National Institute of Blood Disease and Bone Marrow Transplantation)
  • Published : 2016.12.01
⟨ Previous Next ⟩

Abstract

Background: Diagnostic karyotyping analysis is routinely used in acute myeloid leukemia (AML) clinics. Categorization of patients into risk stratified groups (favorable, intermediate and adverse) according to cytogenetic findings can serve as a valuable independent prognostic factor. Method and Material: A retrospective descriptive study was conducted based on the patient records of newly diagnosed non-M3 AML young adult cases undergoing standard 3+7 i.e, Daunorubicin and Ara-C (DA) as remission induction chemotherapy. Diagnostic cytogenetic analysis reports were analyzed to classify the patients into risk stratified groups according to South West Oncology Group criteria and prognostic significance was measured with reference to achievement of haematological remission after 1st induction chemotherapy. Results:A normal karyotype was commonly expressed, found in 47.2% of patients, while 65% (n=39) appeared to have intermediate risk cytogenetics, and 13.3% (n=8) adverse or unclassified findings. Favourable cytogenetics was least frequent in the patient cohort, accounting for only 8.3 % (n=5).The impact of cytogenetic risk groups on achievement of haematological remission was evaluated by applying Pearson Chi-square, and was found to be non-significant (df=12, p=0.256) but when the outcomes of favourable risk groups with intermediate, adverse and unclassified findings compared, results were highly significant (df=6, p=0.000) for each comparison. In patients of the favourable cytogenetic risk group, HR?? was reported in 40% (n=2/5), as compared to 62.2% (n=23/37) in the intermediate cytogenetic risk group, 57.1% (n=4/7) in the adverse cytogenetic risk group and 28.6% (n=2/7) in hte unclassified cytogenetic risk group. Conclusion: Cytogenetic risk stratification for AML cases following criteria provided by international guidelines did not produce conclusive results in our Pakistani patients. However, we cannot preclude an importance as the literature clearly supports the use of pretreatment karyotyping analysis as a significant predictive marker for clinical outcomes. The apparent differences between Pakistani and Western studies indicate an urgent need to develop risk stratification guidelines according to the specific cytogenetic makeup of South Asian populations.

Keywords

References

  1. Ahmad F, Mohota R, Sanap S, Mandava S, Das BR (2014). Molecular evaluation of DNMT3A and IDH1/2 gene mutation: frequency, distribution pattern and associations with additional molecular markers in normal karyotype Indian acute myeloid leukemia patients. Asian Pac J CancerPrev, 15, 1247-53. https://doi.org/10.7314/APJCP.2014.15.3.1247
  2. Anwar M, Ayub M, Iqbal H (2006). Frequency of genetic abnormalities in patients of acute myeloid leukemia. Pak J Pathol, 17, 25-8.
  3. Appelbaum FR, Gundacker H, Head DR, et al (2006). Age and acute myeloid leukemia. Blood, 107, 3481-5 https://doi.org/10.1182/blood-2005-09-3724
  4. Asif N, Hassan K (2013). Acute myeloid leukemia amongst adults. J Islamabad Med Dental College, 2, 58-63.
  5. Aziz F, Qureshi I (2008). Clinical and cytogenetic analyses in Pakistani leukemia patients. Pak J Zool, 40, 147-57.
  6. Bennett JM, Catovsky D, Daniel MT, et al (1985). Proposed revised criteria for the classification of acute myeloid leukaemia. A report of the French-American-British cooperative group. Ann Intern Med, 103, 620-5. https://doi.org/10.7326/0003-4819-103-4-620
  7. Breems DA, Van Putten WL, De Greef GE, et al (2008). Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol, 26, 4791-7. https://doi.org/10.1200/JCO.2008.16.0259
  8. Byrd J, Mrozek K, Dodge R, et al (2002). Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group (CALGB8461). Blood, 100, 4325-36. https://doi.org/10.1182/blood-2002-03-0772
  9. Cheson BD, Bennett JM, Kopecky KJ, et al (2003). Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute Myeloid Leukemia. J Clin Oncol, 21, 4642-9. https://doi.org/10.1200/JCO.2003.04.036
  10. Cheson BD, Cassileth PA, Head DR, et al (1990). Report of the national cancer institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol, 8, 813-9. https://doi.org/10.1200/JCO.1990.8.5.813
  11. Dohner H, Estey EH, Amadori S, et al (2010). Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European Leukemia Network. Blood, 115, 453-74. https://doi.org/10.1182/blood-2009-07-235358
  12. Erba HP (2010). Has there been progress in the treatment of older patients with acute myeloid leukemia?. Best Pract Res Clin Haematol, 23, 495-501 https://doi.org/10.1016/j.beha.2010.09.012
  13. Estey E, Dohner H (2006). Acute myeloid leukaemia. Lancet, 368, 1894-907. https://doi.org/10.1016/S0140-6736(06)69780-8
  14. Estey EH (2014). Acute myeloid leukemia: 2014 update on riskstratification and management. Am J Hematol, 89, 1063-81. https://doi.org/10.1002/ajh.23834
  15. Fernandez HF, Sun Z, Yao X, et al (2009). Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med, 361, 1249-59. https://doi.org/10.1056/NEJMoa0904544
  16. Foran JM (2010). New prognostic markers in acute myeloid leukemia: perspective from the clinic. Hematology. Am Soc Hematol Educ Program, 2010, 47-55.
  17. Grimwade D, Hills R, Moorman A, et al (2010). Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood, 116, 354-65. https://doi.org/10.1182/blood-2009-11-254441
  18. Harani MS, Adil SN, Shaikh MU, et al (2006). Significance of cytogenetic abnormalities in acute myeloid leukemia. J Pak Med Assoc, 56, 9.
  19. Harris NL, Jaffe ES, Diebold J, et al (1999). World Health Organization classification of neoplastic diseases of haematopoietic and lymphoid tissue: report of the clinical advisory committee meeting Airlie House, Virginia, November 1997. J Clin Oncol, 17, 3835-49. https://doi.org/10.1200/JCO.1999.17.12.3835
  20. Haskell CM (1995). Cancer treatment. In 'Cytogenetics and molecular biology of the acute myeloid leukemia'. W.B Saunders Company, Pheladelphia, pp 905-10.
  21. Hou H, Lin C, Chou W, et al (2013). Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia. Leukemia, 28, 50-8.
  22. Kakepoto GN, Burney IA, Zaki S, et al (2002). Long-term outcomes of acute myeloid leukemia in adults in Pakistan. J Pak Med Assoc, 52, 482-6.
  23. Kottaridis PD, Gale RE, Frew ME, et al (2001). The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood, 98, 1752-9. https://doi.org/10.1182/blood.V98.6.1752
  24. Kumar C (2011). Genetic abnormalities and challenges in the treatment of acute myeloid leukemia. Genes Cancer, 2, 95-107. https://doi.org/10.1177/1947601911408076
  25. Naseem N, Imtiaz U, Mobeen S (2013). Evaluation of frequency and clinico-hematological features of acute myeloid leukemia at a tertiary care hospital, lahore. Pak J Med Health Sci, 7, 347-9.
  26. NCI, National Cancer Institute. Adult acute myeloid leukemia (PDQR): treatment. Health Professional Version. Available from: http://www.cancer.gov/cancertopics/pdq/treatment/ adultAML/healthprofessional/allpages; 2014.
  27. O'Donnell M, Abboud C, Altman J, et al (2012). Acute Myeloid Leukemia; clinical practice guidelines in oncology. J Natl Compr Canc Netw, 10, 984-1021. https://doi.org/10.6004/jnccn.2012.0103
  28. Oken MM, Creech RH, Tromy DC, et al (1982). Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol, 5, 649-56. https://doi.org/10.1097/00000421-198212000-00014
  29. Orozco JJ, Applebaum FR (2012). Unfavourable, complex, and monosomal karyotypes:the most challenging forms of acute myeloid leukemia. Oncology, 26, 706-12.
  30. Patel JP, Gonen M, Figueroa ME, et al (2012). Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Eng J Med, 366, 1079-89. https://doi.org/10.1056/NEJMoa1112304
  31. Shahab F, Raziq F (2014). Clinical presentation of acute leukemia. J Coll Physicians Surg Pak, 24, 472-6.
  32. Shahab S, Qadar Z , Nadeem M, et al (2015). Overall Survival in Acute Myeloid Leukaemia Patients with and without Internal Tandem Duplication. Asian Pac J Cancer Prev, 16, 381. https://doi.org/10.7314/APJCP.2015.16.1.381
  33. Slovak M, Kopecky K, Cassileth P, et al (2000). Karyotyping analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a South Oncology Group/Eastern Cooperative Oncology Group study. Blood, 96, 4075-83.
  34. Su L, Gao SJ, Tan YH, Han W, Li W (2013). Associations between age, cytogenetics, FLT3-ITD, and marrow leukemia cells identified by flow cytometry. Asian Pac J Cancer Prev, 14, 5341-4. https://doi.org/10.7314/APJCP.2013.14.9.5341
  35. Sultan S, Zaheer HA, Irfan SM, Ashar S(2016). Demographic and clinical characteristics of adult acute Myeloid Leukemia-tertiary care experience. Asian Pac J Cancer Prev, 17, 357-60. https://doi.org/10.7314/APJCP.2016.17.1.357
  36. Vardiman JW , Thiele J, Arber DA, et al (2009). The 2008 revision of the world health organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood, 114, 937-51. https://doi.org/10.1182/blood-2009-03-209262